Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment Onward Therapeutics has gained EMA approval for its subsidiary Emercell to conduct clinical trials for its innovative NK cell therapy, OT-C001, targeting cancer.

Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment #Switzerland #Onward_Therapeutics #Emercell #OT-C001 #Epalinges